Phase III trial shows ceritinib to be superior to chemotherapy as first-line treatment for advanced ALK-rearranged NSCLC

By ecancer reporter Clare Sansom A large majority of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC); this tumour type has a better prognosis than small-cell lung cancer, although five-year survival rates only range from 50%...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kQCC72
via IFTTT